Sublime
An inspiration engine for ideas
At first I didn't realize how big this was, until I read the fine print: TLDR with the insights baked in:
OpenAI has developed a novel language model called GPT-4b micro, specifically designed for protein engineering in collaboration with Retro Biosciences, a longevity research company backed by Sam Altman's $180 millio... See more
David Shapiro ⏩x.com
Page Not Found | PLOS Biology
journals.plos.org
Excellent blog post by @jacobkimmel on why pharma progress has slowed down over the last many decades, and why some people are optimistic about a big speedup over the next few years.
Eroom's Law (coined by @jackscn) says that the number of drugs per billion dollars decline two-fold every nine years.
___LIN... See more
Today we report in @NatureBiotech the development of dual-AAV in vivo delivery systems for prime editors that can support efficient prime editing in multiple organs such as brain, liver, and heart.
1/4 https://t.co/lSInTkYBiv
Let me tell you a story. It'll end up at the current tech-bio and protein design scene.
But the story starts about 25 years earlier.
Did you know that, commercially, the human genome project precipitated the end and not the start of a genomics boom? 1/
Rohit Singhx.com
Dallas-based Colossal Biosciences, the self-described de-extinction company behind the woolly mammoth and thylacine, today announced that it is spinning off Form Bio, as an independent software company offering a computational life sciences platform that bridges the gap between data and discovery.